CTEV logo

Claritev Corporation Stock Price

NYSE:CTEV Community·US$440.5m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

CTEV Share Price Performance

US$25.84
-12.70 (-32.95%)
US$39.80
Fair Value
US$25.84
-12.70 (-32.95%)
35.1% undervalued intrinsic discount
US$39.80
Fair Value
Price US$25.84
AnalystConsensusTarget US$39.80
AnalystLowTarget US$22.00
AnalystHighTarget US$86.00

CTEV Community Narratives

·
Fair Value US$39.8 35.1% undervalued intrinsic discount

Analysts Boost Claritev Valuation Amid Growth Optimism and Strategic Developments

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$22 17.5% overvalued intrinsic discount

Rising Regulation And Cost Burdens Will Strain US Healthcare Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$86 70.0% undervalued intrinsic discount

Aging Global Population And Digital Health Will Transform Diagnostics

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$86
70.0% undervalued intrinsic discount
Profit Margin
13.12%
Future PE
15.15x
Price in 2028
US$118.92

Trending Discussion

Updated Narratives

CTEV logo

CTEV: Early FY26 Contracts And DOJ Probe Will Shape Execution Outlook

Fair Value: US$22 17.5% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CTEV logo

CTEV: Volume Resilience And 2026 Buybacks Will Support Future Upside

Fair Value: US$39.8 35.1% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CTEV logo

Aging Global Population And Digital Health Will Transform Diagnostics

Fair Value: US$86 70.0% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with slight risk.

4 Risks
2 Rewards

Claritev Corporation Key Details

US$978.8m

Revenue

US$262.1m

Cost of Revenue

US$716.7m

Gross Profit

US$1.0b

Other Expenses

-US$286.5m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-16.81
73.23%
-29.27%
-2,012.5%
View Full Analysis

About CTEV

Founded
1980
Employees
3000
CEO
Travis Dalton
WebsiteView website
www.claritev.com

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services. It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.

Recent CTEV News & Updates

Narrative Update May 27

CTEV: Early FY26 Contracts And DOJ Probe Will Shape Execution Outlook

Analysts have lifted their Claritev price target to $40 from $21, pointing to stronger early FY26 contract wins and new customer additions as key drivers behind the updated fair value estimate of $22 and a higher future P/E assumption. Analyst Commentary Recent research points to improving sentiment around Claritev, with analysts highlighting early FY26 contract wins of US$44m in annual contract value and six new customer additions as key supports for the higher fair value estimate and revised P/E assumption behind the US$40 price target.

Recent updates

No updates